Biotechnology

Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities

March 19, 2026 8:55 AM

OSR Holdings, Inc. (NASDAQ:OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary, Woori IO Co., Ltd. ("Woori IO"), has entered into a mutual non-disclosure agreement ("NDA") with Sinopharm Group Beijing Huahong ("Sinopharm"), the Beijing-based unit of Sinopharm Group and major state-owned healthcare and pharmaceutical distribution enterprise of China. This announcement is being...

Read more

Faron Pharmaceuticals Ltd: Director Dealing

March 19, 2026 3:30 AM

Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Juho Jalkanen, CEO of the Company, subscribed 23,656 ordinary shares in Faron at price of EUR 0.5 per share on 17 March 2026, pursuant to the rights issue announced by the Company on 10 March 2026. Additionally, Juho Jalkanen subscribed 4,860 ordinary shares in Faron at a price of EUR 0.5...

Read more

Faron Pharmaceuticals Ltd: Director Dealing

March 19, 2026 3:25 AM

Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Yrjö Wichmann, other senior manager of the Company, acquired 10,000 ordinary shares in Faron at price of EUR 0.51942 per share on 17 March 2026. Further details are set out in the Notification of Dealing Form below. For more information, please contact: IR Partners, Finland (Media) Kare...

Read more

Faron Pharmaceuticals Ltd: Director Dealing

March 19, 2026 3:20 AM

Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Pacta sunt servanda Oy, an entity wholly owned by Vesa Karvonen, General Counsel of the Company, subscribed 72,000 ordinary shares in Faron at price of EUR 0.5 per share on 18 March 2026, pursuant to the rights issue announced by the Company on 10 March 2026. Further details are set out in...

Read more

MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank 

March 19, 2026 2:35 AM

MindMaze Therapeutics Holding SA (SIX:MMTX) (the Company), a global leader in brain technology and precision neurotherapeutics, today announced that Baader Bank has initiated equity research coverage on the Company's shares. Baader Bank has initiated coverage with a Buy recommendation and a target price of CHF 1.80 per share. This new coverage complements the existing research coverage provided by Edison Group, which currently values the Company...

Read more

FluoGuide Receives FDA Fast Track Designation for FG001 in High-Grade Glioma

March 18, 2026 4:45 PM

FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to FG001 as an intraoperative imaging agent to guide surgical resection of high-grade glioma. U.S. FDA Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious...

Read more

Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability

March 18, 2026 9:10 AM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced an important validation and de-risking milestone for its cell-free biomanufacturing platform: An independent partner, Cayman Chemical, successfully ran eXoZymes' technology at pilot scale and achieved results consistent with - and in some cases exceeding - earlier...

Read more

IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026

March 18, 2026 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced it will demonstrate its Agentic Harmonization Assistant ("AHA"), an artificial intelligence platform designed to automate the integration and analysis of complex biomedical datasets, at the Alzheimer's & Parkinson's Diseases Conference (ADPD) 2026. The demonstration will take...

Read more

Edison Oncology to Present Two Posters at the 2026 AACR Annual Meeting

March 18, 2026 9:00 AM

Edison Oncology Holding Corp. ("Edison Oncology" or the "Company") today announced the presentation of two posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, in San Diego, California. The presentations showcased Edison Oncology's advancements in precision oncology, including EO1001, an irreversible pan-ErbB TKI with CNS penetration, and EO4426, a brain-penetrant dual inhibitor...

Read more

New data from Investigator‑Initiated Study Evaluating Alligator Bioscience's Mitazalimab to be Presented at AACR Annual Meeting 2026

March 18, 2026 4:05 AM

Alligator Bioscience (STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced that new data from a Phase 1 investigator‑initiated trial (IIT) evaluating intratumoral mitazalimab administered in conjunction with irreversible electroporation (IRE) in locally advanced pancreatic ductal adenocarcinoma (PDAC) will be presented at the American Association for Cancer Research (AACR)...

Read more

New AACR Data Expand Evidence for TKa In Immunotherapy-Treated Patients and CDK Inhibitor Dose Optimization

March 18, 2026 3:25 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based biomarkers for cancer treatment monitoring, today announces two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting. The studies expand the evidence for circulating thymidine kinase activity (TKa), measured with Biovica's DiviTum® TKa assay, as a pharmacodynamic biomarker in oncology drug development. New data in...

Read more

Biovica International AB - Q3 Interim Report Nov 2025-Jan2026

March 18, 2026 3:15 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) 46% growth with strong momentum in the USA and for Pharma Services Q3 (Nov 2025-Jan 2026) (comparison figures are for the same period 2024/2025) Net sales amounted to SEK 3,294 (2,261), corresponding to an increase of 46%. In local currency, net sales increased by approximately 60%. Cash flow from operating activities amounted to SEK -11,517 (- 17,445) thousand. At the end of the...

Read more

ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results

March 17, 2026 4:05 PM

ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its fourth quarter and full year ended December 31, 2025. 2025 Full Year and Fourth Quarter Highlights Reported fourth quarter revenue of $10.4 million, including $1.2 million of IRRAflow revenue, representing 34% overall growth and 19%...

Read more

NAYA Therapeutics Announces World-Class Board of Directors

March 17, 2026 10:30 AM

NAYA Therapeutics, a clinical-stage biopharmaceutical company dedicated to pioneering the next generation of cancer therapies through the development of astatine-211 (²¹¹At) targeted alpha therapies and natural killer (NK) cell engaging bifunctional antibodies, today announced that it has elected a new board of directors to support its management team as it accelerates company growth towards transformative clinical milestones. "We are thrilled...

Read more

Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400%

March 17, 2026 8:30 AM

Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced it has developed a new manufacturing process for its lead product, GelrinC®, an off-the-shelf hydrogel synchronized erosion and resorbable implant for the treatment of painful injuries to focal articular knee cartilage. The proprietary new process does not require the use of...

Read more

Microbix Presents Reference-Material Innovations at EUROGIN

March 17, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF)(Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is presenting results of novel QUANTDx™ reference materials designed to emulate real-life human papillomavirus ("HPV") patient-samples and thereby better support the validation of molecular (e.g., "PCR") tests for infection. Microbix is presenting at EUROGIN, an international conference and exhibition focused upon...

Read more

Melius MicroBiomics Receives Australian DIR Licence as Key Step Toward Clinical Evaluation

March 16, 2026 10:58 AM

Melius MicroBiomics Inc., a biotechnology company spun out of The University of British Columbia's (UBC) Okanagan campus, today announced that Australia's Office of the Gene Technology Regulator (OGTR) has granted a Dealings Involving Intentional Release (DIR) licence, authorizing the controlled clinical use of its engineered microbial therapeutic in Australia. The DIR licence was granted to Melius MicroBiomics Pty Ltd, the Company's wholly...

Read more

uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy

March 16, 2026 7:00 AM

uBriGene Biosciences (uBriGene), a global CDMO leader, is excited to announce that its strategic partner, Grit Biotechnologies, has received FDA clearance for its Investigational New Drug (IND) application on GT307, a next-generation gene-edited Tumor-Infiltrating Lymphocytes (TIL) therapy. uBriGene played a key role in enabling this milestone, providing tech transfer, process development, GMP manufacturing, and regulatory support to advance...

Read more

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

March 13, 2026 8:00 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the year ended December 31, 2025. Recent Highlights Expanded and presented preclinical and translational evidence supporting neutrophil extracellular traps (NETs) as drivers of cancer progression and...

Read more

eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium

March 12, 2026 4:15 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced that Perriman will present a solution for scaling production of NCT, a naturally occurring small molecule currently being developed by eXoZymes for both nutraceutical and pharmaceutical applications. The presentation will focus on NCT's potential role in metabolic...

Read more